Host Susceptibility and Molecular Epidemiology

  • Li-E Wang
  • Guojun Li
  • Erich Sturgis
  • Qingyi Wei

Abstract

Tobacco and alcohol exposures are major determinants of risk of squamous cell carcinoma of the head and neck (SCCHN), accounting for approximately threefourths of all oral and pharyngeal cancers in the U.S. and an even higher attributable fraction of laryngeal cancers [1] . Othe r exposures include human papillomavirus, dietary, occupational, medical, and other factors that may also contribute to the etiology of this disease; however, only a fraction of exposed individuals will develop SCCHN. Therefore, the role of genetic susceptibility to carcinogenic exposures must be factored into the risk assessment process. This chapter explores some of the host factors that modulate susceptibility to epithelial carcinogenesis induced by tobacco and alcohol exposures and describes some relevant molecular epidemiology association studies of single nucleotide polymorphism (SNP) and risk of SCCHN.

Keywords

PAHs Adduct Smoke Estradiol Histidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr (1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 48:3282–3287PubMedGoogle Scholar
  2. 2.
    Ankathil R, Mathew A, Joseph F, Nair MK (1996) Is oral cancer susceptibility inherited? Report of five oral cancer families. Eur J Cancer B Oral Oncol 32B:63–67PubMedGoogle Scholar
  3. 3.
    Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL (1995) Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case–control study. Int J Cancer 63:769–773PubMedGoogle Scholar
  4. 4.
    Morita M, Kuwano H, Nakashima T, Taketomi A, Baba H, Saito T, Tomoda H, Egashira A, Kawaguchi H, Kitamura K, Sugimachi K (1998) Family aggregation of carcinoma of the hypopharynx and cervical esophagus: special reference to multiplicity of cancer in upper aerodigestive tract. Int J Cancer 76:468–471PubMedGoogle Scholar
  5. 5.
    Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K (2002) Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract. Surgery 131:S1–S6PubMedGoogle Scholar
  6. 6.
    Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA (1996) Familial risks of squamous cell carcinoma of the head and neck: retrospective case–control study. BMJ 313:716–721PubMedGoogle Scholar
  7. 7.
    Brown LM, Gridley G, Diehl SR, Winn DM, Harty LC, Otero EB, Fraumeni JF Jr, Hayes RB (2001) Family cancer history and susceptibility to oral carcinoma in Puerto Rico. Cancer 92:2102–2108PubMedGoogle Scholar
  8. 8.
    Goldstein AM, Blot WJ, Greenberg RS, Schoenberg JB, Austin DF, Preston-Martin S, Winn DM, Bernstein L, McLaughlin JK, Fraumeni JF Jr (1994) Familial risk in oral and pharyngeal cancer. Eur J Cancer B Oral Oncol 30B:319–322PubMedGoogle Scholar
  9. 9.
    Hussain SK, Sundquist J, Hemminki K (2008) Familial clustering of cancer at human papillomavirus- associated sites according to the Swedish Family-Cancer Database. Int J Cancer 122:1873–1878PubMedGoogle Scholar
  10. 10.
    Mork J, Moller B, Glattre E (1999) Familial risk in head and neck squamous cell carcinoma diagnosed before the age of 45: a population-based study. Oral Oncol 35:360–367PubMedGoogle Scholar
  11. 11.
    Li X, Hemminki K (2003) Familial upper aerodigestive tract cancers: incidence trends, familial clustering and subsequent cancers. Oral Oncol 39:232–239PubMedGoogle Scholar
  12. 12.
    Negri E, Boffetta P, Berthiller J, Castellsague X, Curado MP, Maso LD, Daudt AW, Fabianova E, Fernandez L, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Koifman S, Lazarus P, Lence JJ, Levi F, Mates D, Matos E, Menezes A, Muscat J, Eluf-Neto J, Olshan AF, Rudnai P, Shangina O, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Zaridze D, Lissowska J, Zhang ZF, Ferro G, Brennan P, La Vecchia C, Hashibe M (2008) Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 124:394–401Google Scholar
  13. 13.
    Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, Hoover RN, Weston A, Harris CC (1993) Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2:481–485PubMedGoogle Scholar
  14. 14.
    Andreasson L, Bjorlin G, Hocherman M, Korsgaard R, Trell E (1987) Laryngeal cancer, aryl hydrocarbon hydroxylase inducibility and smoking. A follow-up study. ORL J Otorhinolaryngol Relat Spec 49:187–192Google Scholar
  15. 15.
    Andreasson L, Bjorlin G, Laurell P, Trell E, Korsgaard R (1985) Oral and oropharyngeal cancer, aryl hydrocarbon hydroxylase inducibility and smoking. A follow-up study. ORL J Otorhinolaryngol Relat Spec 47:131–138Google Scholar
  16. 16.
    Brandenburg JH, Kellermann G (1978) Aryl hydrocarbon hydroxylase inducibility in laryngeal carcinoma. Arch Otolaryngol 104:151–152PubMedGoogle Scholar
  17. 17.
    Jaiswal AK, Gonzalez FJ, Nebert DW (1985) Human P1–450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids Res 13:4503–4520PubMedGoogle Scholar
  18. 18.
    Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW (1991) Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48:720–725PubMedGoogle Scholar
  19. 19.
    Sato M, Sato T, Izumo T, Amagasa T (1999) Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 20:1927–1931PubMedGoogle Scholar
  20. 20.
    Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T (1999) Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 35:191–196PubMedGoogle Scholar
  21. 21.
    Nakachi K, Imai K, Hayashi S, Kawajiri K (1993) Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53:2994–2999PubMedGoogle Scholar
  22. 22.
    Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Bath J, Worrall SF, Hand P, Fryer AA, Strange RC (1998) Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 8:91–100PubMedGoogle Scholar
  23. 23.
    Oude Ophuis MB, van Lieshout EM, Roelofs HM, Peters WH, Manni JJ (1998) Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 82:936–943Google Scholar
  24. 24.
    Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H (1992) Pointmutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1:485–489PubMedGoogle Scholar
  25. 25.
    Sugimura H, Suzuki I, Hamada GS, Iwase T, Takahashi T, Nagura K, Iwata H, Watanabe S, Kino I, Tsugane S (1994) Cytochrome P-450 lA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarkers Prev 3:145–148PubMedGoogle Scholar
  26. 26.
    Hayashi S, Watanabe J, Kawajiri K (1992) High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83:866–870PubMedGoogle Scholar
  27. 27.
    Cosma G, Crofts F, Taioli E, Toniolo P, Garte S (1993) Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40:309–316PubMedGoogle Scholar
  28. 28.
    Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K, Kawamoto T (1999) Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 83:606–609PubMedGoogle Scholar
  29. 29.
    Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, Miki H, Fujii T, Yoshino K, Kusuoka H, Monden M (1999) Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 80:685–688PubMedGoogle Scholar
  30. 30.
    Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, Pike V, Richie JP Jr, Lazarus P (1997) CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 6:791–797PubMedGoogle Scholar
  31. 31.
    Hashibe M, Brennan P, Strange RC, Bhisey R, Cascorbi I, Lazarus P, Oude Ophuis MB, Benhamou S, Foulkes WD, Katoh T, Coutelle C, Romkes M, Gaspari L, Taioli E, Boffetta P (2003) Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 12:1509–1517PubMedGoogle Scholar
  32. 32.
    Ho T, Wei Q, Sturgis EM (2007) Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 29:682–699PubMedGoogle Scholar
  33. 33.
    Varela-Lema L, Taioli E, Ruano-Ravina A, Barros-Dios JM, Anantharaman D, Benhamou S, Boccia S, Bhisey RA, Cadoni G, Capoluongo E, Chen CJ, Foulkes W, Goloni-Bertollo EM, Hatagima A, Hayes RB, Katoh T, Koifman S, Lazarus P, Manni JJ, Mahimkar M, Morita S, Park J, Park KK, Pavarino Bertelli EC, de Souza Fonseca Ribeiro EM, Roy B, Spitz MR, Strange RC, Wei Q, Ragin CC (2008) Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med 10:369–384PubMedGoogle Scholar
  34. 34.
    Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9:3–28PubMedGoogle Scholar
  35. 35.
    Ko Y, Abel J, Harth V, Brode P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Thier R, Sachinidis A, Vetter H, Bolt HM, Herberhold C, Bruning T (2001) Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 61:4398–4404PubMedGoogle Scholar
  36. 36.
    Li G, Liu Z, Sturgis EM, Chamberlain RM, Spitz MR, Wei Q (2005) CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 14:1034–1036PubMedGoogle Scholar
  37. 37.
    Singh AP, Shah PP, Mathur N, Buters JT, Pant MC, Parmar D (2007) Genetic polymorphisms in Cytochrome P4501B1 and susceptibility to Head and Neck Cancer. Mutat Res 639(1–2):11–9PubMedGoogle Scholar
  38. 38.
    Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169–170PubMedGoogle Scholar
  39. 39.
    Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12:1197–1201PubMedGoogle Scholar
  40. 40.
    Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ, Muschik GM, Green- Gallo L, Buivys D, Aisner S et al (1990) Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 82:1264–1272PubMedGoogle Scholar
  41. 41.
    Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M (1988) Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 66(Suppl 11):87–97PubMedGoogle Scholar
  42. 42.
    Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529–532PubMedGoogle Scholar
  43. 43.
    Spina E, Campo GM, Avenoso A, Caputi AP, Zuccaro P, Pacifici R, Gatti G, Strada G, Bartoli A, Perucca E (1994) CYP2D6-related oxidation polymorphism in Italy. Pharmacol Res 29:281–289PubMedGoogle Scholar
  44. 44.
    Agundez JA, Gallardo L, Ledesma MC, Lozano L, Rodriguez-Lescure A, Pontes JC, Iglesias- Moreno MC, Poch J, Ladero JM, Benitez J (2001) Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 61:59–63PubMedGoogle Scholar
  45. 45.
    Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K (2005) CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 574:112–123PubMedGoogle Scholar
  46. 46.
    Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, Jones PW, Hand P, Gilford J, Farrell WE, Hoban P, Fryer AA, Strange RC (1998) Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 8:433–439PubMedGoogle Scholar
  47. 47.
    Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E (1998) Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 51:294–298PubMedGoogle Scholar
  48. 48.
    Gronau S, Koenig-Greger D, Jerg M, Riechelmann H (2003) Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 128:674–680PubMedGoogle Scholar
  49. 49.
    Lieber CS (1999) Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968– 1998) – a review. Alcohol Clin Exp Res 23:991–1007PubMedGoogle Scholar
  50. 50.
    Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA (1994) Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European- Americans and Taiwanese. Pharmacogenetics 4:185–192PubMedGoogle Scholar
  51. 51.
    Bouchardy C, Hirvonen A, Coutelle C, Ward PJ, Dayer P, Benhamou S (2000) Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 87:734–740PubMedGoogle Scholar
  52. 52.
    Gattas GJ, de Carvalho MB, Siraque MS, Curioni OA, Kohler P, Eluf-Neto J, Wunsch-Filho V (2006) Genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. Head Neck 28:819–826PubMedGoogle Scholar
  53. 53.
    Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, Hildesheim A, Chen CJ (1997) Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 6:901–905PubMedGoogle Scholar
  54. 54.
    Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, Lin DX (2000) Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prev 9:551–556PubMedGoogle Scholar
  55. 55.
    Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M, Arzani D, De Lauretis A, Cattel C, Almadori G, van Duijn CM, Paludetti G, Ricciardi G (2008) CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol 134:93–100PubMedGoogle Scholar
  56. 56.
    Marques CF, Koifman S, Koifman RJ, Boffetta P, Brennan P, Hatagima A (2006) Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case–control study in Rio de Janeiro. Oral Oncol 42:632–637PubMedGoogle Scholar
  57. 57.
    Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K (2005) The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett 224:263–278PubMedGoogle Scholar
  58. 58.
    Harth V, Schafer M, Abel J, Maintz L, Neuhaus T, Besuden M, Primke R, Wilkesmann A, Thier R, Vetter H, Ko YD, Bruning T, Bolt HM, Ickstadt K (2008) Head and neck squamouscell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 71:887–897PubMedGoogle Scholar
  59. 59.
    Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14:1821–1824PubMedGoogle Scholar
  60. 60.
    Seidegard J, Vorachek WR, Pero RW, Pearson WR (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 85:7293–7297PubMedGoogle Scholar
  61. 61.
    Roots I, Brockmoller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Investig 70:307–319PubMedGoogle Scholar
  62. 62.
    Nomura T, Noma H, Shibahara T, Yokoyama A, Muramatusu T, Ohmori T (2000) Aldehyde dehydrogenase 2 and glutathione S-transferase M 1 polymorphisms in relation to the risk for oral cancer in Japanese drinkers. Oral Oncol 36:42–46PubMedGoogle Scholar
  63. 63.
    Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP Jr, Lazarus P (2000) Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics 10:123–131PubMedGoogle Scholar
  64. 64.
    Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H (1995) Glutathione s-transferase genotypes as risk factors for head and neck cancer. Am J Surg 170:499–501PubMedGoogle Scholar
  65. 65.
    Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q (1999) Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 84:220–224PubMedGoogle Scholar
  66. 66.
    Li D, Wang LE, Chang P, El-Naggar AK, Sturgis EM, Wei Q (2007) In vitro benzo[a]pyrene diol epoxide-induced DNA adducts and risk of squamous cell carcinoma of head and neck. Cancer Res 67:5628–5634PubMedGoogle Scholar
  67. 67.
    Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33:177–182PubMedGoogle Scholar
  68. 68.
    Tripathy CB, Roy N (2006) Meta-analysis of glutathione S-transferase M1 genotype and risk toward head and neck cancer. Head Neck 28:217–224PubMedGoogle Scholar
  69. 69.
    Hiyama T, Yoshihara M, Tanaka S, Chayama K (2008) Genetic polymorphisms and head and neck cancer risk (Review). Int J Oncol 32:945–973PubMedGoogle Scholar
  70. 70.
    Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, Ketterer B (1991) Theta, a new class of glutathione transferases purified from rat and man. Biochem J 274(Pt 2):409–414PubMedGoogle Scholar
  71. 71.
    Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300(Pt 1):271–276PubMedGoogle Scholar
  72. 72.
    Geisler SA, Olshan AF (2001) GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am J Epidemiol 154:95–105PubMedGoogle Scholar
  73. 73.
    Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012Google Scholar
  74. 74.
    Boukouvala S, Sim E (2005) Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 96:343–351PubMedGoogle Scholar
  75. 75.
    Olshan AF, Weissler MC, Watson MA, Bell DA (2000) GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 9:185–191PubMedGoogle Scholar
  76. 76.
    Fronhoffs S, Bruning T, Ortiz-Pallardo E, Brode P, Koch B, Harth V, Sachinidis A, Bolt HM, Herberhold C, Vetter H, Ko Y (2001) Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck. Carcinogenesis 22:1405–1412PubMedGoogle Scholar
  77. 77.
    Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 88:5237–5241PubMedGoogle Scholar
  78. 78.
    Deguchi T (1992) Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 267:18140–18147PubMedGoogle Scholar
  79. 79.
    Drozdz M, Gierek T, Jendryczko A, Pilch J, Piekarska J (1987) N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma 34:481–484PubMedGoogle Scholar
  80. 80.
    Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA (1998) A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19:1803–1807PubMedGoogle Scholar
  81. 81.
    Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM (2001) N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 22:1993–1999PubMedGoogle Scholar
  82. 82.
    Agundez JA (2008) Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 9:520–531PubMedGoogle Scholar
  83. 83.
    Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA (1996) Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 17:160–162PubMedGoogle Scholar
  84. 84.
    Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG (1992) Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 84:414–422PubMedGoogle Scholar
  85. 85.
    Janot F, Massaad L, Ribrag V, de Waziers I, Beaune PH, Luboinski B, Parise O Jr, Gouyette A, Chabot GG (1993) Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma. Carcinogenesis 14:1279–1283PubMedGoogle Scholar
  86. 86.
    Hassett C, Aicher L, Sidhu JS, Omiecinski CJ (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3:421–428PubMedGoogle Scholar
  87. 87.
    Smith CA, Harrison DJ (1997) Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630–633PubMedGoogle Scholar
  88. 88.
    Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, Hirvonen A (2000) High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 60:534–536PubMedGoogle Scholar
  89. 89.
    Lacko M, Roelofs HM, Te Morsche RH, Voogd AC, Oude Ophuis MB, Peters WH, Manni JJ (2008) Microsomal epoxide hydrolase genotypes and the risk for head and neck cancer. Head Neck 30:836–844PubMedGoogle Scholar
  90. 90.
    Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, Hong WK, Roth JA (1993) Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 53:1676–1683PubMedGoogle Scholar
  91. 91.
    Brennan P, Lewis S, Hashibe M, Bell DA, Boffetta P, Bouchardy C, Caporaso N, Chen C, Coutelle C, Diehl SR, Hayes RB, Olshan AF, Schwartz SM, Sturgis EM, Wei Q, Zavras AI, Benhamou S (2004) Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. Am J Epidemiol 159:1–16PubMedGoogle Scholar
  92. 92.
    Harty LC, Caporaso NE, Hayes RB, Winn DM, Bravo-Otero E, Blot WJ, Kleinman DV, Brown LM, Armenian HK, Fraumeni JF Jr, Shields PG (1997) Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst 89:1698–1705PubMedGoogle Scholar
  93. 93.
    Coutelle C, Ward PJ, Fleury B, Quattrocchi P, Chambrin H, Iron A, Couzigou P, Cassaigne A (1997) Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 99:319–325PubMedGoogle Scholar
  94. 94.
    Yokoyama A, Muramatsu T, Ohmori T, Yokoyama T, Okuyama K, Takahashi H, Hasegawa Y, Higuchi S, Maruyama K, Shirakura K, Ishii H (1998) Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 19:1383–1387PubMedGoogle Scholar
  95. 95.
    Sturgis EM, Dahlstrom KR, Guan Y, Eicher SA, Strom SS, Spitz MR, Wei Q (2001) Alcohol dehydrogenase 3 genotype is not associated with risk of squamous cell carcinoma of the oral cavity and pharynx. Cancer Epidemiol Biomarkers Prev 10:273–275PubMedGoogle Scholar
  96. 96.
    Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Janout V, Fabianova E, Bencko V, Moullan N, Chabrier A, Hung R, Hall J, Canzian F, Brennan P (2006) Evidence for an important role of alcohol- and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 15:696–703PubMedGoogle Scholar
  97. 97.
    Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M (2008) Case–control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck 30:1139–1147PubMedGoogle Scholar
  98. 98.
    Reszka E, Czekaj P, Adamska J, Wasowicz W (2008) Relevance of glutathione S-transferase M1 and cytochrome P450 1A1 genetic polymorphisms to the development of head and neck cancers. Clin Chem Lab Med 46(8):1090–1096PubMedGoogle Scholar
  99. 99.
    Hagmar L, Brogger A, Hansteen IL, Heim S, Hogstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I et al (1994) Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54:2919–2922PubMedGoogle Scholar
  100. 100.
    Hsu TC, Cherry LM, Samaan NA (1985) Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet Cytogenet 17:307–313PubMedGoogle Scholar
  101. 101.
    Hsu TC, Spitz MR, Schantz SP (1991) Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1:83–89PubMedGoogle Scholar
  102. 102.
    Schantz SP, Hsu TC (1989) Mutagen-induced chromosome fragility within peripheral blood lymphocytes of head and neck cancer patients. Head Neck 11:337–342PubMedGoogle Scholar
  103. 103.
    Schantz SP, Hsu TC, Ainslie N, Moser RP (1989) Young adults with head and neck cancer express increased susceptibility to mutagen-induced chromosome damage. JAMA 262:3313–3315PubMedGoogle Scholar
  104. 104.
    Schantz SP, Spitz MR, Hsu TC (1990) Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst 82:1773–1775PubMedGoogle Scholar
  105. 105.
    Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang ZF, Tobi H, Braakhuis BJ, Snow GB (1996) Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 88:530–535PubMedGoogle Scholar
  106. 106.
    Wang LE, Sturgis EM, Eicher SA, Spitz MR, Hong WK, Wei Q (1998) Mutagen sensitivity to benzo(a)pyrene diol epoxide and the risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 4:1773–1778PubMedGoogle Scholar
  107. 107.
    Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR (2002) Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 62:2813–2818PubMedGoogle Scholar
  108. 108.
    Xiong P, Hu Z, Li C, Wang LE, El-Naggar AK, Sturgis EM, Wei Q (2007) In vitro benzo[a] pyrene diol epoxide-induced DNA damage and chromosomal aberrations in primary lymphocytes, smoking, and risk of squamous cell carcinoma of the head and neck. Int J Cancer 121:2735–2740PubMedGoogle Scholar
  109. 109.
    Wang LE, Xiong P, Zhao H, Spitz MR, Sturgis EM, Wei Q (2008) Chromosome instability and risk of squamous cell carcinomas of head and neck. Cancer Res 68:4479–4485PubMedGoogle Scholar
  110. 110.
    Athas WF, Hedayati MA, Matanoski GM, Farmer ER, Grossman L (1991) Development and field-test validation of an assay for DNA repair in circulating human lymphocytes. Cancer Res 51:5786–5793PubMedGoogle Scholar
  111. 111.
    Slebos RJ, Taylor JA (2001) A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines. Biochem Biophys Res Commun 281:212–219PubMedGoogle Scholar
  112. 112.
    Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L (1993) DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci U S A 90:1614–1618PubMedGoogle Scholar
  113. 113.
    Alcalay J, Freeman SE, Goldberg LH, Wolf JE (1990) Excision repair of pyrimidine dimers induced by simulated solar radiation in the skin of patients with basal cell carcinoma. J Invest Dermatol 95:506–509PubMedGoogle Scholar
  114. 114.
    Wei Q, Spitz MR, Gu J, Cheng L, Xu X, Strom SS, Kripke ML, Hsu TC (1996) DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev 5:199–204PubMedGoogle Scholar
  115. 115.
    Sturgis EM, Clayman GL, Guan Y, Guo Z, Wei Q (1999) DNA repair in lymphoblastoid cell lines from patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 125:185–190PubMedGoogle Scholar
  116. 116.
    Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q (1998) Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 7:465–468PubMedGoogle Scholar
  117. 117.
    Wiencke JK (2002) DNA adduct burden and tobacco carcinogenesis. Oncogene 21:7376–7391PubMedGoogle Scholar
  118. 118.
    Li D, Firozi PF, Chang P, Wang LE, Xiong P, Sturgis EM, Eicher SA, Spitz MR, Hong WK, Wei Q (2001) In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck. Int J Cancer 93:436–440PubMedGoogle Scholar
  119. 119.
    Zhao H, Wang LE, Li D, Chamberlain RM, Sturgis EM, Wei Q (2008) Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxideinduced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype–phenotype correlation analysis. Carcinogenesis 29:1560–1566PubMedGoogle Scholar
  120. 120.
    Wei Q, Eicher SA, Guan Y, Cheng L, Xu J, Young LN, Saunders KC, Jiang H, Hong WK, Spitz MR, Strom SS (1998) Reduced expression of hMLH1 and hGTBP/hMSH6: a risk factor for head and neck cancer. Cancer Epidemiol Biomarkers Prev 7:309–314PubMedGoogle Scholar
  121. 121.
    Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q (2002) Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 94:393–397PubMedGoogle Scholar
  122. 122.
    Wei Q, Wang LE, Sturgis EM, Mao L (2005) Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 14:1961–1966PubMedGoogle Scholar
  123. 123.
    Sancar A (1996) DNA excision repair. Annu Rev Biochem 65:43–81PubMedGoogle Scholar
  124. 124.
    Kraemer KH, Lee MM, Andrews AD, Lambert WC (1994) The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 130:1018–1021Google Scholar
  125. 125.
    Neumann AS, Sturgis EM, Wei Q (2005) Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 42:65–92PubMedGoogle Scholar
  126. 126.
    Ramachandran S, Ramadas K, Hariharan R, Rejnish Kumar R, Radhakrishna Pillai M (2006) Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 42:350–362PubMedGoogle Scholar
  127. 127.
    Kietthubthew S, Sriplung H, Au WW, Ishida T (2006) Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health 209:21–29PubMedGoogle Scholar
  128. 128.
    Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S, Mitsudo K, Ueda M, Tajima K, Ishizaki K (2006) Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 35:11–18PubMedGoogle Scholar
  129. 129.
    Bau DT, Tsai MH, Huang CY, Lee CC, Tseng HC, Lo YL, Tsai Y, Tsai FJ (2007) Relationship between polymorphisms of nucleotide excision repair genes and oral cancer risk in Taiwan: evidence for modification of smoking habit. Chin J Physiol 50:294–300PubMedGoogle Scholar
  130. 130.
    An J, Liu Z, Hu Z, Li G, Wang LE, Sturgis EM, El-Naggar AK, Spitz MR, Wei Q (2007) Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 16:1633–1638PubMedGoogle Scholar
  131. 131.
    Zhang D, Chen C, Fu X, Gu S, Mao Y, Xie Y, Huang Y, Li Y (2008) A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. J Hum Genet 53:18–33PubMedGoogle Scholar
  132. 132.
    Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price P, Waldron J, Goldstein D, Meyer F, Bairati I, Liu G (2008) Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 17:490–499PubMedGoogle Scholar
  133. 133.
    Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374PubMedGoogle Scholar
  134. 134.
    Hung RJ, Hall J, Brennan P, Boffetta P (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 162:925–942PubMedGoogle Scholar
  135. 135.
    Kurumizaka H, Ikawa S, Nakada M, Enomoto R, Kagawa W, Kinebuchi T, Yamazoe M, Yokoyama S, Shibata T (2002) Homologous pairing and ring and filament structure formation activities of the human Xrcc2*Rad51D complex. J Biol Chem 277:14315–14320PubMedGoogle Scholar
  136. 136.
    Lieber MR, Ma Y, Pannicke U, Schwarz K (2003) Mechanism and regulation of human nonhomologous DNA end-joining. Nat Rev Mol Cell Biol 4:712–720PubMedGoogle Scholar
  137. 137.
    Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM (2005) DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 115:2221–2231PubMedGoogle Scholar
  138. 138.
    Olshan AF, Watson MA, Weissler MC, Bell DA (2002) XRCC1 polymorphisms and head and neck cancer. Cancer Lett 178:181–186PubMedGoogle Scholar
  139. 139.
    Duan Z, Shen H, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Spitz MR, Wei Q (2002) DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 11:1142–1143PubMedGoogle Scholar
  140. 140.
    Li C, Hu Z, Lu J, Liu Z, Wang LE, El-Naggar AK, Sturgis EM, Spitz MR, Wei Q (2007) Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer 110:867–875PubMedGoogle Scholar
  141. 141.
    Benhamou S, Tuimala J, Bouchardy C, Dayer P, Sarasin A, Hirvonen A (2004) DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 112:901–904PubMedGoogle Scholar
  142. 142.
    Werbrouck J, De Ruyck K, Duprez F, Van Eijkeren M, Rietzschel E, Bekaert S, Vral A, De Neve W, Thierens H (2008) Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res 656:74–81PubMedGoogle Scholar
  143. 143.
    Lu J, Wang LE, Xiong P, Sturgis EM, Spitz MR, Wei Q (2007) 172G>T variant in the 5 ¢ untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. Carcinogenesis 28:988–994PubMedGoogle Scholar
  144. 144.
    Chiu CF, Tsai MH, Tseng HC, Wang CL, Tsai FJ, Lin CC, Bau DT (2008) A novel single nucleotide polymorphism in ERCC6 gene is associated with oral cancer susceptibility in Taiwanese patients. Oral Oncol 44:582–586PubMedGoogle Scholar
  145. 145.
    Tseng HC, Tsai MH, Chiu CF, Wang CH, Chang NW, Huang CY, Tsai CW, Liang SY, Wang CL, Bau DT (2008) Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res 28:1687–1691PubMedGoogle Scholar
  146. 146.
    Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, Lin YC, Wen CH, Chiang WF, Ho CH, Chen HC, Wang ST, Lin CW, Chang HW (2008) Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med 37:271–277PubMedGoogle Scholar
  147. 147.
    Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, Lazarus P (2002) The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 23:1229–1234PubMedGoogle Scholar
  148. 148.
    Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, Ueyama Y, Yamashita H, Hinoda Y (2006) Interaction of OGG1 Ser326Cys polymorphism with cigarette smoking in head and neck squamous cell carcinoma. Mol Carcinog 45:344–348PubMedGoogle Scholar
  149. 149.
    Zhang Z, Shi Q, Wang LE, Sturgis EM, Spitz MR, El-Naggar AK, Hong WK, Wei Q (2004) No Association between hOGG1 Ser326Cys polymorphism and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 13:1081–1083PubMedGoogle Scholar
  150. 150.
    Zhai X, Zhao H, Liu Z, Wang LE, El-Naggar AK, Sturgis EM, Wei Q (2008) Functional variants of the NEIL1 and NEIL2 genes and risk and progression of squamous cell carcinoma of the oral cavity and oropharynx. Clin Cancer Res 14:4345–4352PubMedGoogle Scholar
  151. 151.
    Ulrich CM (2005) Nutrigenetics in cancer research – folate metabolism and colorectal cancer. J Nutr 135:2698–2702PubMedGoogle Scholar
  152. 152.
    Herbig K, Chiang EP, Lee LR, Hills J, Shane B, Stover PJ (2002) Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J Biol Chem 277:38381–38389PubMedGoogle Scholar
  153. 153.
    Schirch L, Peterson D (1980) Purification and properties of mitochondrial serine hydroxymethyltransferase. J Biol Chem 255:7801–7806PubMedGoogle Scholar
  154. 154.
    Shane B (1989) Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 45:263–335PubMedGoogle Scholar
  155. 155.
    Girgis S, Nasrallah IM, Suh JR, Oppenheim E, Zanetti KA, Mastri MG, Stover PJ (1998) Molecular cloning, characterization and alternative splicing of the human cytoplasmic serine hydroxymethyltransferase gene. Gene 210:315–324PubMedGoogle Scholar
  156. 156.
    Neumann AS, Lyons HJ, Shen H, Liu Z, Shi Q, Sturgis EM, Shete S, Spitz MR, El-Naggar A, Hong WK, Wei Q (2005) Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: a case–control analysis. Int J Cancer 115:131–136PubMedGoogle Scholar
  157. 157.
    Zhang Z, Shi Q, Sturgis EM, Spitz MR, Hong WK, Wei Q (2004) Thymidylate synthase 5 ¢ – and 3 ¢ -untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 10:7903–7910PubMedGoogle Scholar
  158. 158.
    Zhang Z, Shi Q, Liu Z, Sturgis EM, Spitz MR, Wei Q (2005) Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case–control analysis. Cancer Epidemiol Biomarkers Prev 14:1188–1193PubMedGoogle Scholar
  159. 159.
    Capaccio P, Ottaviani F, Cuccarini V, Cenzuales S, Cesana BM, Pignataro L (2005) Association between methylenetetrahydrofolate reductase polymorphisms, alcohol intake and oropharyngolaryngeal carcinoma in northern Italy. J Laryngol Otol 119:371–376PubMedGoogle Scholar
  160. 160.
    Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K, Saito T, Sato S, Ueda R, Tajima K (2007) One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case–control study. Cancer Sci 98:1439–1446PubMedGoogle Scholar
  161. 161.
    Scully C, Field JK, Tanzawa H (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 36:256–263Google Scholar
  162. 162.
    Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799PubMedGoogle Scholar
  163. 163.
    Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677PubMedGoogle Scholar
  164. 164.
    Nakahara Y, Shintani S, Mihara M, Kiyota A, Ueyama Y, Matsumura T (2000) Alterations of Rb, p16(INK4A) and cyclin D1 in the tumorigenesis of oral squamous cell carcinomas. Cancer Lett 160:3–8PubMedGoogle Scholar
  165. 165.
    Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, Frazier ML, Spitz MR, Wei Q (2001) Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case–control study. Carcinogenesis 22:1195–1199PubMedGoogle Scholar
  166. 166.
    Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W, Szyfter K (2006) Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol 263:43–48PubMedGoogle Scholar
  167. 167.
    Ralhan R, Agarwal S, Mathur M, Wasylyk B, Srivastava A (2000) Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin Cancer Res 6:2440–2447PubMedGoogle Scholar
  168. 168.
    Li G, Sturgis EM, Wang LE, Chamberlain RM, Amos CI, Spitz MR, El-Naggar AK, Hong WK, Wei Q (2004) Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 25:1911–1916PubMedGoogle Scholar
  169. 169.
    Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, Wei Q (2005) Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 26:1596–1602PubMedGoogle Scholar
  170. 170.
    Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12:5596–5602PubMedGoogle Scholar
  171. 171.
    Chen K, Zhao H, Hu Z, Wang LE, Zhang W, Sturgis EM, Wei Q (2008) CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 14:6343–6349PubMedGoogle Scholar
  172. 172.
    Li G, Sturgis EM, Wang LE, Chamberlain RM, Spitz MR, El-Naggar AK, Hong WK, Wei Q (2004) Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin Cancer Res 10:3996–4002PubMedGoogle Scholar
  173. 173.
    Scully C, Field JK, Tanzawa H (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncol 36:404–413PubMedGoogle Scholar
  174. 174.
    Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103PubMedGoogle Scholar
  175. 175.
    Street D, Delgado G (1995) The role of p53 and HPV in cervical cancer. Gynecol Oncol 58:287–288PubMedGoogle Scholar
  176. 176.
    Andersson S, Rylander E, Strand A, Sallstrom J, Wilander E (2001) The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer 85:1153–1156PubMedGoogle Scholar
  177. 177.
    Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M (1999) Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354:218–219PubMedGoogle Scholar
  178. 178.
    Couch ME, Ferris RL, Brennan JA, Koch WM, Jaffee EM, Leibowitz MS, Nepom GT, Erlich HA, Sidransky D (2007) Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin Cancer Res 13:7199–7206PubMedGoogle Scholar
  179. 179.
    Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085–1089PubMedGoogle Scholar
  180. 180.
    Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229–234PubMedGoogle Scholar
  181. 181.
    Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW (2008) MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol 87:243–252PubMedGoogle Scholar
  182. 182.
    Brant O, Hoffmann M, Kanappilly A, Gorogh T, Gottschlich S (2007) P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. Anticancer Res 27:3301–3305PubMedGoogle Scholar
  183. 183.
    Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, Wei Q, Li G (2008) p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis 29:875–879PubMedGoogle Scholar
  184. 184.
    Perrone F, Mariani L, Pastore E, Orsenigo M, Suardi S, Marcomini B, DaRiva L, Licitra L, Carbone A, Pierotti MA, Pilotti S (2007) p53 codon 72 polymorphisms in human papillomavirus- negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer 109:2461–2465PubMedGoogle Scholar
  185. 185.
    Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, Wei Q (2007) Singlenucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 28:2008–2012PubMedGoogle Scholar
  186. 186.
    Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, Wei Q (2007) Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 13:4300–4305PubMedGoogle Scholar
  187. 187.
    Huang WY, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, Chanock SJ, Fraumeni JF Jr, Hayes RB (2005) Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 14:1747–1753PubMedGoogle Scholar
  188. 188.
    Li C, Wang LE, Wei Q (2008) DNA repair phenotype and cancer susceptibility – a mini review. Int J CancerGoogle Scholar
  189. 189.
    Zhang Z, Shi Q, Sturgis EM, Spitz MR, Wei Q (2005) Polymorphisms and haplotypes of serine hydroxymethyltransferase and risk of squamous cell carcinoma of the head and neck: a case–control analysis. Pharmacogenet Genomics 15:557–564PubMedGoogle Scholar
  190. 190.
    Kaghad M, Bonnet H et al (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90(4):809–819PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Li-E Wang
    • 1
  • Guojun Li
    • 1
  • Erich Sturgis
    • 1
  • Qingyi Wei
    • 1
  1. 1.Department of EpidemiologyThe University of Texas, M. D. Anderson Cancer CenterHouston, TXUSA

Personalised recommendations